Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
After reviewing the Groups forecast financial performance and financing arrangements, the Directors consider that the Group has adequate resources to continue operating for at least 12 months from the date of approval of this preliminary announcement and that it is therefore appropriate to continue to adopt the going concern basis in preparing the Group's 2025 Annual Report
FDA Funding Opportunity Announcements FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed) FOA Number : PAR-19-306 Next Application Due Date : April 12, 2020 Letter of Intent Due Date : Eight weeks before application due date The Scientific Conference Grant Program recognizes the value of small, high quality conferences and scientific meetings that are relevant to FDAs mission and to public health
Developmental toxicity of nicotine: a transdisciplinary synthesis and implications for emerging tobacco products
Policies like this highlight how legislation can shape long-term population health outcomes and protect future generations
& Ribisl, K
US$ 25.20
US$ 22.30
US$ 21.93
US$ 29.43
US$ 27.73
US$ 21.25
US$ 29.59
US$ 29.28
US$ 20.39